GOVX Rasio cepet GeoVax Labs, Inc.

The share price history of GeoVax Labs, Inc. (GOVX) on the GURU.Markets platform currently stands at 1.57. The business capitalization relies on the development of oncology and antiviral treatments for government procurement and the WHO. While MVA-based vaccine development is conducted in collaboration with the NIH and DoD, high R&D expenses force GeoVax Labs, Inc. (GOVX) to raise capital through equity offerings and grants.

The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, excluding slow-moving inventories. By analyzing the quick ratio, an investor can gauge the financial stability of GeoVax Labs, Inc. (GOVX), where resource optimization aligned with ESG principles and bioethics enables a balance between laboratory operational efficiency and the protection of capital against funding shortages.